Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
The British Committee for Standards in Haematology (BCSH) Guidelines for myelofibrosis were produced in 2012 (Reilly et al, 2012) , but since then Ruxolitinib, a JAK1/JAK2 inhibitor, has been approved for use in the European Union and highly prevalent mutations in the Calreticulin gene (CALR) have been described. We therefore wish to revise the existing guideline (Reilly et al, 2012) to accommodate this important data. Current diagnostic criteria should be modified to incorporate testing for the CALR mutations into major criteria A2 alongside JAK2 V617F, as shown in Table I (Evidence grade 1A). Patients with CALR mutations may have a better prognosis (Klampfl et al, 2013) , but this has not formally been assessed and incorporated into prognostic scores.
Substantial data are now available concerning responses to JAK inhibitor therapies including beneficial effects upon survival (Verstovsek et al, 2012 Cervantes et al, 2013) . For example, at 144 weeks in the COMFORT-II study the median of overall survival had not been reached in either arm. A total of 29 (19Á9%) and 22 (30Á1%) patients died during the study in the ruxolitinib and best available therapy (BAT) arms, respectively, of which deaths on treatment were reported for 13 (8Á9%) in the ruxolitinib arm, and 5 (6Á8%) in the BAT arm (one death occurred after crossover to ruxolitinib). There was a 52% reduction in risk of death in the ruxolitinib treatment arm compared to the BAT arm (Haz-ard Ratio = 0Á48, 95% confidence interval 0Á28-0Á85). The estimated probability of being alive at 144 weeks was 81% in ruxolitinib arm and 61% in BAT arm. The P-value for the log-rank test stratified by the baseline risk category was 0Á009, (Cervantes et al, 2013) . Furthermore, data from these randomized studies suggest that standard therapies are comparable to placebo in terms of spleen and symptom responses. The previous guideline (Reilly et al, 2012) recommended consideration of JAK inhibitor therapy for patients who have failed hydroxycarbamide therapy and are not presently suitable for bone marrow transplantation, or for patients with severe constitutional symptoms. In view of new evidence we now formally recommend ruxolitinib as first line therapy for symptomatic splenomegaly and/or myelofibrosisrelated constitutional symptoms regardless of JAK2 V617F mutation status (evidence grade 1A) where the balance between need to resolve the latter outweighs risk of side effects and, in particular, we make the following recommendations:
Indications: Whilst treatment with ruxolitinib is suggested to confer a survival advantage treatment with this agent in asymptomatic patients and/or those who lack bothersome splenomegaly is not currently recommended.
Tolerance and side effects:
1 Anaemia and thrombocytopenia are to be anticipated with this agent, anaemia usually peaking by weeks 12-16 and improving thereafter. In patients with pre-existing anaemia and thrombocytopenia (NB, those patients with platelet counts below 50 9 10 9 /l are excluded from using this drug) a lower starting dose is recommended for example 5 mg BD Monitoring response:
1 For objective monitoring of symptoms, a tool such as the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)may be useful (Emanuel et al, 2012; Harrison et al, 2013) . (evidence grade 1A) 2 Recent response criteria for testing novel myelofibrosis treatments have been suggested for use in clinical trials (Tefferi et al, 2013) , although these are not intended or recommended for use in clinical practice. 3 The decision to stop ruxolitinib therapy will depend upon a combination of different factors, including benefit upon treatment target (usually spleen and/or symptoms) and presence or absence of toxicity. The degree of target spleen or symptom reduction has not yet been identified and will be individual for each patient. It is recommended that the dose should be modified to the maximum tolerated where response is not adequate and that treatment should be continued for 24 weeks. A schematic for considering whether to continue or stop these agents is suggested in Fig 1. (evidence grade 1B) How to stop 1 Disease symptoms and splenomegaly will recur on drug withdrawal, sometimes rapidly. A gradual dose tapering over 7-10 d and avoidance of sudden interruptions are recommended. Cover with systemic steroids (suggestion 20-30 mg of prednisolone) has also been used in these circumstances . (evidence grade 1A)
For patients failing or intolerant of ruxolitinib, additional JAK inhibitors are being assessed in clinical trials and may be approved in the future.
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